4.4 USD
+0.46 (+11.68%)
4.46 USD
+0.06 (+1.36%)
DFFN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DFFN as it has an excellent financial health rating, but there are worries on the profitability. DFFN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- DFFN had negative earnings in the past year.
- DFFN had a negative operating cash flow in the past year.
1.2 Ratios
- The profitability ratios for DFFN are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- DFFN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for DFFN remains at a similar level compared to 1 year ago.
- DFFN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- DFFN has an Altman-Z score of -11.66. This is a bad value and indicates that DFFN is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -11.66, DFFN is doing worse than 82.42% of the companies in the same industry.
- DFFN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.66 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- DFFN has a Current Ratio of 10.71. This indicates that DFFN is financially healthy and has no problem in meeting its short term obligations.
- DFFN has a better Current ratio (10.71) than 75.43% of its industry peers.
- A Quick Ratio of 10.71 indicates that DFFN has no problem at all paying its short term obligations.
- DFFN has a better Quick ratio (10.71) than 75.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.71 |
3. Growth
3.1 Past
- DFFN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.04%, which is quite impressive.
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 14.80% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.57%
EPS Next 2Y9.39%
EPS Next 3Y21.86%
EPS Next 5Y14.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- DFFN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year DFFN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- DFFN's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.39%
EPS Next 3Y21.86%
5. Dividend
5.1 Amount
- No dividends for DFFN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DIFFUSION PHARMACEUTICALS IN / DFFN FAQ
Can you provide the ChartMill fundamental rating for DIFFUSION PHARMACEUTICALS IN?
ChartMill assigns a fundamental rating of 2 / 10 to DFFN.
What is the valuation status of DIFFUSION PHARMACEUTICALS IN (DFFN) stock?
ChartMill assigns a valuation rating of 1 / 10 to DIFFUSION PHARMACEUTICALS IN (DFFN). This can be considered as Overvalued.
How profitable is DIFFUSION PHARMACEUTICALS IN (DFFN) stock?
DIFFUSION PHARMACEUTICALS IN (DFFN) has a profitability rating of 0 / 10.
What is the financial health of DIFFUSION PHARMACEUTICALS IN (DFFN) stock?
The financial health rating of DIFFUSION PHARMACEUTICALS IN (DFFN) is 7 / 10.